How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

23,466 results for

Breast Cancer Staging

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III Breast Cancer

Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III Breast Cancer Guideline 1-14 Version 3 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III Breast Cancer A. Arnaout, N. Varela, M. Allarakhia, L. Grimard, A. Hey, J. Lau, L. Thain, A. Eisen, and the Staging in Early Stage Breast Cancer Advisory Committee 1 Report Date: October 7, 2019 (...) (Vancouver Style): Arnaout A, Varela NP, Allarakhia M, Grimard L, Hey A, et al. Baseline staging imaging for distant metastasis in women with stage I, II, and III breast cancer. Toronto (ON): Cancer Care Ontario; 2019 October 7. Program in Evidence- Based Care Guideline No.: 1-14 Version 3. Copyright This report is copyrighted by Cancer Care Ontario; the report and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves

2019 Cancer Care Ontario

2. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer P Pertuzumab for adjuvant treatment of ertuzumab for adjuvant treatment of HER2-positiv HER2-positive early stage breast cancer e early stage breast cancer T echnology appraisal guidance Published: 20 March 2019 nice.org.uk/guidance/ta569 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

3. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial) (PubMed)

An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial) An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial) Journals Library (...) An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} After conservative breast surgery for early breast cancer, targeted intra-operative radiotherapy was non-inferior in terms of local

Full Text available with Trip Pro

2016 NIHR HTA programme

4. Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness and Guidelines

Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness and Guidelines Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness and Guidelines Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness (...) and Guidelines Last updated: February 5, 2019 Project Number: RB1307-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of combination therapy in adults with any stage of breast cancer? What are the evidence-based guidelines associated with the use of combination therapy in adults with any stage of breast cancer? Key Message Two systematic reviews (one with a meta-analysis), 15 non-randomized studies, and one

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Observational study: Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality

Observational study: Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality Article Text Diagnosis

2017 Evidence-Based Medicine (Requires free registration)

6. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO (...) .19.00945 Journal of Clinical Oncology - published online before print May 31, 2019 PMID: Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx , MD, PhD 1 x Fabrice Andre ; , MD 2 x Nofisat Ismaila ; , MD, PhD 3 x N. Lynn Henry ; , PhD 2 x Mark R. Somerfield ; , MD 4 x Robert C. Bast ; , PhD 5 x William Barlow ; 6 x Deborah E. Collyar ; , MD 7 x M. Elizabeth Hammond

2019 American Society of Clinical Oncology Guidelines

7. Clinical utility of genomic signatures in early-stage breast cancer

Clinical utility of genomic signatures in early-stage breast cancer Clinical utility of genomic signatures in early-stage breast cancer - INAHTA Brief

2019 Haute Autorite de sante

8. Clinical utility of genomic signatures in early-stage breast cancer

Clinical utility of genomic signatures in early-stage breast cancer INAHTA Brief Issue 2019 Title Clinical utility of genomic signatures in early-stage breast cancer Agency HAS, French National Authority for Health (Haute Autorité de santé) 5 avenue du Stade de France – F 93218 La Plaine Cedex, France Tel: +33 (0)1 55 93 70 00, contact.seap@has-santé.fr, www.has-sante.fr Reference ISBN number 978-2-11-152376-0, link to full report https://www.has-sante.fr/portail/jcms/c_2748998/fr/utilite (...) results (validity, clinical applicability) and future prospects were discussed with a multidisciplinary expert working group 4 . Stakeholders were consulted during the document review phase (professional organisations, patient associations, National Cancer Institute). Conclusions and recommendations were reviewed by the Medical 3 Patients presenting with HR+/HER2- breast cancer staged pT1c-2 pN0-1, and who are likely to receive ACT in usual care on the basis of true uncertainty or established

2019 Haute Autorite de sante

9. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage, Operable Breast Cancer

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage, Operable Breast Cancer Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO (...) .19.00948 Journal of Clinical Oncology - published online before print June 17, 2019 PMID: Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline , MD, PhD 1 x N. Lynn Henry ; , PhD 2 x Mark R. Somerfield ; , MD 3 x Vandana G. Abramson ; , MD 2 x Nofisat Ismaila ; , MD 4 x Kimberly H. Allison ; , MD 5 x Carey K. Anders ; , MS, MFA 6 x Diana T. Chingos ; , MD 7 x Andrea

2019 American Society of Clinical Oncology Guidelines

10. Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women.

Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women. American College of Radiology End User License Agreement ACR Appropriateness Criteria is a registered trademark of the American College of Radiology. By accessing the ACR Appropriateness Criteria®, you expressly agree and consent to the terms and conditions as described at: http://www.acr.org/~/media/ACR/Documents/AppCriteria/TermsandConditions.pdf Personal use of material (...) Cancer American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women Variant 1: Newly diagnosed. Initial workup. Rule out bone metastases. Radiologic Procedure Rating Comments RRL* FDG-PET/CT whole body 2 ???? Tc-99m bone scan whole body 1 ??? X-ray skeletal survey 1 ??? Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually

2019 American College of Radiology

11. Gene Expression Tests for Women with Early Stage Breast Cancer: A Review of Clinical Utility and Cost-Effectiveness

Gene Expression Tests for Women with Early Stage Breast Cancer: A Review of Clinical Utility and Cost-Effectiveness Gene Expression Tests for Women with Early Stage Breast Cancer: A Review of Clinical Utility and Cost-Effectiveness | CADTH.ca Find the information you need Gene Expression Tests for Women with Early Stage Breast Cancer: A Review of Clinical Utility and Cost-Effectiveness Gene Expression Tests for Women with Early Stage Breast Cancer: A Review of Clinical Utility and Cost (...) -Effectiveness Published on: October 16, 2017 Project Number: RC0934-000 Product Line: Research Type: Other Diagnostics Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical utility of gene expression tests to either predict adjunct chemotherapy or evaluate cancer recurrence risk in women with early stage breast cancer? What is the comparative cost-effectiveness of gene expression tests to either predict adjunct chemotherapy or evaluate cancer recurrence

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. Intraoperative Radiotherapy for Early Stage Breast Cancer

Intraoperative Radiotherapy for Early Stage Breast Cancer 1 Public Summary Document Application No. 1429 – Targeted Intraoperative Radiotherapy for Early-Stage Breast Cancer Applicant: Regional Health Care Group Date of MSAC consideration: MSAC 69 th Meeting, 6-7 April 2017 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application requesting extension of the Medicare Benefits Schedule (MBS) item (...) for Intraoperative Radiotherapy (IORT) for early-stage breast cancer to include services delivered using the Xoft® Axxent® (California, USA) device was received by the Department of Health from the Regional Health Care Group. 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation to comparative safety, clinical effectiveness and cost-effectiveness, MSAC did not support public funding of targeted intraoperative radiotherapy (IORT) using the Xoft® Axxent® device

2017 Medical Services Advisory Committee

13. Resection of Cavity Shave Margins in Stage 0-III Breast Cancer Patients Undergoing Breast Conserving Surgery: A Prospective Multicenter Randomized Controlled Trial

Resection of Cavity Shave Margins in Stage 0-III Breast Cancer Patients Undergoing Breast Conserving Surgery: A Prospective Multicenter Randomized Controlled Trial Single-center studies have demonstrated that resection of cavity shave margins (CSM) halves the rate of positive margins and re-excision in breast cancer patients undergoing partial mastectomy (PM). We sought to determine if these findings were externally generalizable across practice settings.In this multicenter randomized (...) controlled trial occurring in 9 centers across the United States, stage 0-III breast cancer patients undergoing PM were randomly assigned to either have resection of CSM ("shave" group) or not ("no shave" group). Randomization occurred intraoperatively, after the surgeon had completed their standard PM. Primary outcome measures were positive margin and re-excision rates.Between July 28, 2016 and April 13, 2018, 400 patients were enrolled in this trial. Four patients (2 in each arm) did not meet inclusion

2019 EvidenceUpdates

14. Adjuvant systemic therapy for early stage (lymph node negative and lymph node positive) breast cancer

Adjuvant systemic therapy for early stage (lymph node negative and lymph node positive) breast cancer CLINICAL PRACTICE GUIDELINE BR-014 Version 5 Adjuvant Systemic Therapy for Early Stage (Lymph Node Negative and Lymph Node Positive) Breast Cancer Effective Date: April, 2018 CLINICAL PRACTICE GUIDELINE BR-014 Version 5 Page 2 of 11 Copyright © (2018) Alberta Health Services This material is protected by Canadian and other international copyright laws. All rights reserved. This material may (...) score:* higher risk 3-5 * Examples: Prosigna TM , OncotypeDx® 6 CLINICAL PRACTICE GUIDELINE BR-014 Version 5 Page 4 of 11 Table 2. Genomic Testing for Systemic Therapy Decision Making* 3-5 Inclusion Criteria Exclusion Criteria • Patient is medically fit to receive adjuvant breast cancer chemotherapy AND • Has early stage resected lymph node negative (including N0i+) or N1mi AND • Either grade 2 or grade 3 invasive breast cancer • Patients unwilling to consider or are medically unfit to receive

2016 CPG Infobase

15. A meta-analysis of the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer. (PubMed)

A meta-analysis of the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer. To systematically evaluate the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis (SLNM) versus patients with stage IIIb/c or IV breast cancer, so as to provide evidence for clinical practice and research.Computer retrieval from PubMed, Cochrane Libratory, CNKI (China National (...) Knowledge Infrastructure), CBM and Wanfang Database with the assistance of other retrieval tools. All the studies evaluating the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer were collected. Quality assessment was performed for the included data based on the quality assessment criteria appropriate for this study. Meta-analysis was performed using RevMan 5.3 software.A total of four references (1277

Full Text available with Trip Pro

2017 Chronic diseases and translational medicine

16. Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer (PubMed)

Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer Breast cancer is a heterogeneous disease. The purpose of adjuvant therapy for early-stage breast cancer is to provide maximum benefit with minimum side effects and not to under-treat or over-treat. The clinical progresses of patients with the same clinical and pathological characteristics who are given similar treatments may show major differences. This fact indicates that the prognostic (...) in addition to endocrine treatment. Several new gene expression analysis studies targeted at gaining the ability to determine drug selection in chemotherapy, endocrine treatment and neo-adjuvant therapy are also currently ongoing. The staging system for new breast cancer that is to be published in the year 2018 also includes gene expression analyses within the prognostic panel and the stage changes depending on the result. The statement 'Treat the patient, not the disease.' is becoming increasingly

Full Text available with Trip Pro

2017 European journal of breast health

17. Breast Cancer Beliefs as Potential Targets for Breast Cancer Awareness Efforts to Decrease Late-Stage Presentation in Uganda (PubMed)

Breast Cancer Beliefs as Potential Targets for Breast Cancer Awareness Efforts to Decrease Late-Stage Presentation in Uganda To assess breast cancer beliefs in Uganda and determine whether these beliefs are associated with factors potentially related to nonparticipation in early detection.A survey with open- and close-ended items was conducted in a community sample of Ugandan women to assess their beliefs about breast cancer. Linear regression was used to ascertain associations between breast (...) cancer beliefs and demographic factors potentially associated with early detection, including socioeconomic factors, health care access, prior breast cancer knowledge, and personal detection practices.Of the 401 Ugandan women surveyed, most had less than a primary school education and received medical care at community health centers. Most women either believed in or were unsure about cultural explanatory models for developing breast cancer (> 82%), and the majority listed these beliefs as the most

Full Text available with Trip Pro

2017 Journal of global oncology

18. Disparities in breast screening, stage at diagnosis, cancer treatment and the subsequent risk of cancer death: a retrospective, matched cohort of aboriginal and non-aboriginal women with breast cancer. (PubMed)

Disparities in breast screening, stage at diagnosis, cancer treatment and the subsequent risk of cancer death: a retrospective, matched cohort of aboriginal and non-aboriginal women with breast cancer. Australia's Aboriginal and Torres Strait Islander women have poorer survival and twice the disease burden from breast cancer compared to other Australian women. These disparities are influenced, but not fully explained, by more diagnoses at later stages. Incorporating breast screening, hospital (...) ; then assess the relationship between screening, treatment and the subsequent risk of breast cancer death.Breast cancers registered among Aboriginal women in South Australia in 1990-2010 (N = 77) were matched with a random selection of non-Aboriginal women by birth and diagnostic year, then linked to screening records, and treatment 2 months before and 13 months after diagnosis. Competing risk regression summarised associations of Aboriginality, breast screening, cancer stage and treatment with risk

2019 BMC health services research

19. Type 2 Diabetes, but Not Insulin (Analog) Treatment, Is Associated With More Advanced Stages of Breast Cancer: A National Linkage of Cancer and Pharmacy Registries

Type 2 Diabetes, but Not Insulin (Analog) Treatment, Is Associated With More Advanced Stages of Breast Cancer: A National Linkage of Cancer and Pharmacy Registries To investigate whether women with type 2 diabetes (T2D) develop a more advanced stage of breast cancer and whether treatment with insulin (analogs) is associated with specific breast cancer characteristics.For this nested case-control study, women with breast cancer diagnosed in 2002-2014 were selected from the linked Netherlands (...) , metastasis), morphology, grade, estrogen receptor and progesterone receptor (PR), human epidermal growth factor receptor 2, and molecular subtype.Women with T2D (n = 1,567) were more often diagnosed with a more advanced tumor stage (odds ratio 1.28 [95% CI 13-1.44]) and a higher grade (1.22 [1.08-1.39]) though less often with a PR-negative breast tumor (0.77 [0.67-0.89]) than women without diabetes (n = 6,267). No associations were found for the other breast cancer characteristics. Women with T2D using

2019 EvidenceUpdates

20. For people who have had early stage breast cancer and who are at high risk for recurrence/mets, are there still no screening methods for Mets beyond waiting for symptoms to occur?

For people who have had early stage breast cancer and who are at high risk for recurrence/mets, are there still no screening methods for Mets beyond waiting for symptoms to occur? Q&A - For people who have had early stage breast cancer and who are at high risk for recurrence/mets, are there still no screening methods for Mets beyond waiting for symptoms to occur? - Trip Database NEW! or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document (...) had early stage breast cancer and who are at high risk for recurrence/mets, are there still no screening methods for Mets beyond waiting for symptoms to occur? 1 Please log in to post a reply Your response: Reply Notes about answers If you see something you feel is wrong, don’t criticise (that misses the point of Triple) courteously and supportively give a counter answer. Answers given should be in good faith, but they should not be considered definitive, be critical. We do not endorse or verify

2019 Trip Community Q&A

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>